Emergent BioSolutions
Clinical trials sponsored by Emergent BioSolutions, explained in plain language.
A biopharmaceutical company specializing in vaccines and medical countermeasures.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Anthrax drug under the microscope: will it save lives? Results expected Jul 2027 (estimated)
- Emergency anthrax drug trial set to launch if outbreak strikes Results expected Jul 2027 (estimated)
- Can a blood product fix smallpox vaccine side effects? Results expected Aug 2027 (estimated)
-
Can a blood product fix smallpox vaccine side effects?
Disease control By invitation onlyThis study looks at whether VIGIV, a blood product with antibodies, helps people who have serious reactions to the smallpox vaccine. It will track 100 patients to see if their skin lesions improve and if their antibody levels change. The goal is to confirm that VIGIV works as a t…
Sponsor: Emergent BioSolutions • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New study checks if botulism antidote is safe and effective for kids
Disease control By invitation onlyThis study looks at how a medicine called BAT® works in children who have or may have been exposed to botulism toxin. The medicine is an antitoxin that helps stop the toxin from causing more harm. Researchers will take blood samples from up to 10 children to see if the dose is ri…
Phase 4 • Sponsor: Emergent BioSolutions • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC